Novel immunotherapies for psoriasis
- 1 January 2002
- journal article
- clinical trial
- Published by Elsevier in Trends in Immunology
- Vol. 23 (1), 47-53
- https://doi.org/10.1016/s1471-4906(01)02119-6
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammationBritish Journal of Dermatology, 2001
- Psoriasis: the plot thickens . . .Nature Immunology, 2001
- VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasisBritish Journal of Dermatology, 2000
- Is psoriasis a neuroimmunologic disease?International Journal of Dermatology, 1999
- The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusionBritish Journal of Dermatology, 1998
- Investigation on a novel and specific leukotriene B4receptor antagonist in the treatment of stable plaque psoriasisBritish Journal of Dermatology, 1998
- A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US studyClinical Therapeutics, 1998
- Lymphocyte Activation in the Pathogenesis of PsoriasisJournal of Investigative Dermatology, 1997
- Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study GroupArchives of Dermatology, 1996
- IMMUNOINTERVENTION IN PSORIASIS WITH ANTI–CD4 ANTIBODIESInternational Journal of Dermatology, 1994